On the public citation graph
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
0 signed · 170 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archinternmed.2007.131openalex-snapshot
Influence of Local Reference Populations on Upper Limits of Normal for Serum Alanine Aminotransferase Levels
inferredcites →https://doi.org/10.1002/hep.20701openalex-snapshot
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
inferredcites →https://doi.org/10.1002/hep.23784openalex-snapshot
Clinical, Laboratory and Histological Associations in Adults with Nonalcoholic Fatty Liver Disease†
inferredcites →https://doi.org/10.1002/hep.27173openalex-snapshot
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep.28431openalex-snapshot
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
inferredcites →https://doi.org/10.1002/hep.31014openalex-snapshot
Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1007/s00125-022-05787-2openalex-snapshot
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferredcites →https://doi.org/10.1016/j.cgh.2021.06.048openalex-snapshot
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.diabres.2021.108884openalex-snapshot
Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study
inferredcites →https://doi.org/10.1016/j.eclinm.2021.101145openalex-snapshot
acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study
inferredcites →https://doi.org/10.1016/j.ejim.2020.08.005openalex-snapshot
Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study
inferredcites →https://doi.org/10.1016/j.eprac.2022.03.010openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferredcites →https://doi.org/10.1016/j.jhep.2018.05.036openalex-snapshot
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
inferredcites →https://doi.org/10.1016/j.jhep.2019.06.021openalex-snapshot
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.jhep.2020.06.025openalex-snapshot
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
inferredcites →https://doi.org/10.1016/j.jhep.2021.05.025openalex-snapshot
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
inferredcites →https://doi.org/10.1016/j.jhep.2021.09.030openalex-snapshot
Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus
inferredcites →https://doi.org/10.1016/j.jhep.2022.03.026openalex-snapshot
Impact of non-invasive biomarkers on hepatology practice: Past, present and future
inferredcites →https://doi.org/10.1016/s0140-6736(20)32511-3openalex-snapshot
Non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/s0140-6736(21)01701-3openalex-snapshot
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
inferredcites →https://doi.org/10.1053/j.gastro.2018.12.036openalex-snapshot
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2021.07.049openalex-snapshot
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1055/s-0042-1751081openalex-snapshot
Noninvasive Algorithms for the Case Finding of “At-Risk” Patients with NAFLD
inferredcites →https://doi.org/10.1056/nejmoa2028395openalex-snapshot
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1056/nejmoa2029349openalex-snapshot
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1111/jgh.14577openalex-snapshot
Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography
inferredcites →https://doi.org/10.1111/liv.13481openalex-snapshot
Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan
inferredcites →https://doi.org/10.1111/liv.13739openalex-snapshot
Diabetes impacts prediction of cirrhosis and prognosis by non‐invasive fibrosis models in non‐alcoholic fatty liver disease
inferredcites →https://doi.org/10.1136/gutjnl-2015-309265openalex-snapshot
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
inferredcites →https://doi.org/10.1371/journal.pmed.1003100openalex-snapshot
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies
inferredcites →https://doi.org/10.2337/dc14-1239openalex-snapshot
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
inferredcites →https://doi.org/10.2337/dc18-s002openalex-snapshot
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
inferredcites →https://doi.org/10.2337/dc19-1071openalex-snapshot
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc20-1997openalex-snapshot
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
inferredcites →https://doi.org/10.2337/dc20-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020
inferredcites →https://doi.org/10.7326/0003-4819-137-1-200207020-00006openalex-snapshot
Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4634800openalex-extracted
Towards Elimination of Chronic Viral Hepatitis in French Polynesia?
inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extracted
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.1002/jmri.70148openalex-snapshot
Fat‐Corrected Non‐Gaussian Diffusion MRI for Liver Fibrosis Assessment in Metabolic Dysfunction‐Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1007/s00125-026-06799-yopenalex-snapshot
Imaging of MASLD: clinical standards and novel methods
inferred← citeshttps://doi.org/10.1007/s00125-026-06816-0openalex-snapshot
Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment
inferred← citeshttps://doi.org/10.1007/s00330-025-11774-zopenalex-snapshot
Ultrasound hepatorenal index for the diagnosis of steatosis in patients with type 2 diabetes: a prospective validation study
inferred← citeshttps://doi.org/10.1007/s00535-024-02179-8openalex-snapshot
Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review
inferred← citeshttps://doi.org/10.1007/s00535-026-02393-6openalex-snapshot
Impact of cardiometabolic criteria on the pathogenesis of MASLD and diagnostic performance of non-invasive tests
inferred← citeshttps://doi.org/10.1007/s11307-026-02130-8openalex-snapshot
Hyperpolarized γ-Glutamyl-[1-13C]Glycine MRI Detects Liver Injury Non-Invasively
inferred← citeshttps://doi.org/10.1007/s11901-025-00713-7openalex-snapshot
Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today’s World
inferred← citeshttps://doi.org/10.1007/s40618-026-03007-xopenalex-snapshot
Epidemiological and socio-economic burden of MASH (previously known as NASH) in Europe: a systematic literature review
inferred← citeshttps://doi.org/10.1016/j.aohep.2024.101501openalex-snapshot
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.cgh.2024.07.011openalex-snapshot
Noninvasive Fibrosis Tests Require Further Evaluation in At-risk Populations
inferred← citeshttps://doi.org/10.1016/j.cgh.2025.02.018openalex-snapshot
Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/j.cgh.2025.09.011openalex-snapshot
Morphometric Quantification of Steatosis and Fibrosis in Metabolic Liver Disease Associated With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/j.clinre.2026.102879openalex-snapshot
Evaluating performance of non-invasive tests for fibrosis detection in MASLD with Type 2 Diabetes Mellitus: Insights from VCTE-Based assessment
inferred← citeshttps://doi.org/10.1016/j.diabet.2025.101709openalex-snapshot
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
inferred← citeshttps://doi.org/10.1016/j.diabres.2024.111820openalex-snapshot
Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD
inferred← citeshttps://doi.org/10.1016/j.diabres.2024.111846openalex-snapshot
Diabetes as a risk factor for MASH progression
inferred← citeshttps://doi.org/10.1016/j.diabres.2025.112151openalex-snapshot
7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.eprac.2025.04.021openalex-snapshot
Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies
inferred← citeshttps://doi.org/10.1016/j.eswa.2025.128816openalex-snapshot
Enhancing decision support for type 2 diabetes mellitus comorbidity risk prediction: An end-to-end multi-task learning model
inferred← citeshttps://doi.org/10.1016/j.gastha.2024.10.017openalex-snapshot
Successful Example of Implementing Screening of Liver Fibrosis in Specialist Diabetes Care
inferred← citeshttps://doi.org/10.1016/j.jceh.2024.102378openalex-snapshot
Visceral Fat and Diabetes: Associations With Liver Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1016/j.jdiacomp.2025.109147openalex-snapshot
The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A cross-sectional study
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.03.023openalex-snapshot
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.04.031openalex-snapshot
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.12.045openalex-snapshot
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
inferred← citeshttps://doi.org/10.1016/j.jhep.2025.01.026openalex-snapshot
Moving diagnosis of liver fibrosis into the community
inferred← citeshttps://doi.org/10.1016/j.jhepr.2023.100845openalex-snapshot
A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.jhepr.2026.101798openalex-snapshot
Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management
inferred← citeshttps://doi.org/10.1016/j.lansea.2026.100753openalex-snapshot
A multicentre survey of liver fibrosis burden in type 2 diabetes in India: the DiaFib-Liver Study
inferred← citeshttps://doi.org/10.1016/j.medj.2025.100700openalex-snapshot
DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population
inferred← citeshttps://doi.org/10.1016/j.mehy.2025.111783openalex-snapshot
13C-methionine breath test for the non-invasive detection of advanced metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.1016/j.metabol.2024.156044openalex-snapshot
Expanding diagnostic and therapeutic horizons for MASH: Comparison of the latest and conventional therapeutic approaches
inferred← citeshttps://doi.org/10.1016/j.metabol.2026.156494openalex-snapshot
Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond
inferred← citeshttps://doi.org/10.1016/j.mmm.2026.06.013openalex-snapshot
Prise en charge des patients atteints de diabète de type 2 et de MASLD : synthèse et position commune selon l’AFEF et la SFD
inferred← citeshttps://doi.org/10.1016/j.soard.2024.12.015openalex-snapshot
Decreased liver volume after bariatric surgery and its positive impact on liver function tests and lipid profile
inferred← citeshttps://doi.org/10.1016/j.xcrm.2024.101820openalex-snapshot
Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.xcrm.2025.102522openalex-snapshot
Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD
inferred← citeshttps://doi.org/10.1016/s0992-5945(24)00025-4openalex-snapshot
Le diabète en France : enjeux cliniques et biologiques actuels
inferred← citeshttps://doi.org/10.1016/s1155-1976(25)43565-7openalex-snapshot
Fibrose hépatique : physiopathologie, diagnostic, pronostic
inferred← citeshttps://doi.org/10.1016/s2468-1253(23)00270-4openalex-snapshot
Implementation of a liver health check in people with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/s2468-1253(24)00313-3openalex-snapshot
Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study
inferred← citeshttps://doi.org/10.1021/acsomega.6c02338openalex-snapshot
Bixin and Montelukast Combination Mitigates the Progression of MASLD to Cytokine-Driven Inflammatory Stress in an In Vitro Fluid-Dynamic Model
inferred← citeshttps://doi.org/10.1038/s41418-024-01410-6openalex-snapshot
ACBP/DBI neutralization for the experimental treatment of fatty liver disease
inferred← citeshttps://doi.org/10.1038/s41467-024-50660-yopenalex-snapshot
A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1038/s41598-024-79428-6openalex-snapshot
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
inferred← citeshttps://doi.org/10.1053/j.gastro.2023.09.015openalex-snapshot
Not All “Normal” Liver Enzymes Are Normal!
inferred← citeshttps://doi.org/10.1055/a-1974-2947openalex-snapshot
Hohe Prävalenz von NASH und fortgeschrittener Fibrosierung bei Typ-2-Diabetes
inferred← citeshttps://doi.org/10.1055/s-0043-1778127openalex-snapshot
Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting
inferred← citeshttps://doi.org/10.1056/aioa2400948openalex-snapshot
Opportunistic Screening of Chronic Liver Disease with Deep-Learning–Enhanced Echocardiography
inferred← citeshttps://doi.org/10.1056/nejmra2403308openalex-snapshot
Noninvasive Assessment of Liver Fibrosis
inferred← citeshttps://doi.org/10.1080/19490976.2024.2302065openalex-snapshot
Prophylactic treatment with Bacteroides uniformis and Bifidobacterium bifidum counteracts hepatic NK cell immune tolerance in nonalcoholic steatohepatitis induced by high fat diet
inferred← citeshttps://doi.org/10.1093/fampra/cmag008openalex-snapshot
Can the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?
inferred← citeshttps://doi.org/10.1096/fj.202402108ropenalex-snapshot
Dodecanedioic acid prevents and reverses metabolic‐associated liver disease and obesity and ameliorates liver fibrosis in a rodent model of diet‐induced obesity
inferred← citeshttps://doi.org/10.1096/fj.202602105ropenalex-snapshot
CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1‐Dependent Suppression of NLRP3
inferred← citeshttps://doi.org/10.1097/aln.0000000000005830openalex-snapshot
Association of Liver Fibrosis Fibrosis-4 Score with Perioperative Complications and Mortality: A Retrospective Multicenter Analysis
inferred← citeshttps://doi.org/10.1097/hep.0000000000000263openalex-snapshot
Diabetes and cirrhosis: Current concepts on diagnosis and management
inferred← citeshttps://doi.org/10.1097/hep.0000000000001400openalex-snapshot
Detecting at-risk steatotic liver disease and liver fibrosis in the community
inferred← citeshttps://doi.org/10.1109/jbhi.2026.3659609openalex-snapshot
DGHME: A Hierarchical Hybrid Expert Multi-Task Learning Model for Disease Grouping in Diabetes Complication Prediction
inferred← citeshttps://doi.org/10.1111/1751-2980.13325openalex-snapshot
Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction–Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1111/apt.17688openalex-snapshot
Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis
inferred← citeshttps://doi.org/10.1111/apt.70401openalex-snapshot
Editorial: An Important Step Towards Mastering Metabolic Dysfunction‐Associated Steatohepatitis‐Targeted Therapy in Diabetes
inferred← citeshttps://doi.org/10.1111/dom.16049openalex-snapshot
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
inferred← citeshttps://doi.org/10.1111/dom.70156openalex-snapshot
Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1111/dom.70168openalex-snapshot
An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1111/hepr.14020openalex-snapshot
Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction‐associated steatotic liver disease
inferred← citeshttps://doi.org/10.1111/imj.70587openalex-snapshot
Discordance between ICD ‐10‐ AM coding and confirmed prevalence of MASLD in a quaternary diabetes service
inferred← citeshttps://doi.org/10.1111/liv.16057openalex-snapshot
Time to move beyond FIB‐4 first for MASLD screening in Type 2 diabetes
inferred← citeshttps://doi.org/10.1111/liv.16224openalex-snapshot
A European Survey to Identify Challenges in the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1111/liv.70514openalex-snapshot
MASLD in Adults With Type 1 Diabetes and Type 2 Diabetes Undergoing Vibration‐Controlled Transient Elastography
inferred← citeshttps://doi.org/10.1111/obr.13663openalex-snapshot
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
inferred← citeshttps://doi.org/10.1124/pharmrev.123.001087openalex-snapshot
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
inferred← citeshttps://doi.org/10.1136/bmj-2023-075179openalex-snapshot
Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention
inferred← citeshttps://doi.org/10.1136/bmjgast-2024-001418openalex-snapshot
Parallel randomised trial testing community fibrosis assessment for suspected non-alcoholic fatty liver disease: outcomes from LOCATE-NAFLD
inferred← citeshttps://doi.org/10.1136/bmjopen-2024-087550openalex-snapshot
Prevalence and characteristics of liver steatosis and fibrosis in type 2 diabetes mellitus (T2DM) patients: a cross-sectional study in populations of eastern China
inferred← citeshttps://doi.org/10.1148/radiol.232416openalex-snapshot
Multiparametric US for Identifying Metabolic Dysfunction–associated Steatohepatitis: A Prospective Multicenter Study
inferred← citeshttps://doi.org/10.1152/ajpgi.00381.2024openalex-snapshot
Microbiota encroachment and a gut-adipose-liver axis in metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.1159/000539371openalex-snapshot
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
inferred← citeshttps://doi.org/10.1177/10806032251338278openalex-snapshot
Delayed Treatment of Misdiagnosed Mushroom Poisoning: Do Organic Anion Transporting Polypeptide Substrates Matter?
inferred← citeshttps://doi.org/10.1186/s12859-025-06263-5openalex-snapshot
Big data dimensionality reduction-based supervised machine learning algorithms for NASH diagnosis
inferred← citeshttps://doi.org/10.1186/s12933-024-02161-xopenalex-snapshot
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts
inferred← citeshttps://doi.org/10.1186/s12933-025-02705-9openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study
inferred← citeshttps://doi.org/10.1186/s40842-023-00163-4openalex-snapshot
Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort
inferred← citeshttps://doi.org/10.1186/s43042-025-00738-zopenalex-snapshot
Pathogenic effects of telomerase reverse transcriptase (TERT) promoter mutations in nonalcoholic steatohepatitis (NASH) related hepatocellular carcinoma (HCC) and its potentials as a diagnostic biomarker
inferred← citeshttps://doi.org/10.1210/endrev/bnag023openalex-snapshot
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
inferred← citeshttps://doi.org/10.12997/jla.2025.14.1.5openalex-snapshot
Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.12997/jla.2025.14.1.69openalex-snapshot
Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1371/journal.pone.0335888openalex-snapshot
Effect of imeglimin on metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes
inferred← citeshttps://doi.org/10.14740/jem935openalex-snapshot
Increased Prevalence of Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease Fibrosis in Type 2 Diabetics Despite Low-Risk Fibrosis-4 Index Scores
inferred← citeshttps://doi.org/10.17235/reed.2025.11545/2025openalex-snapshot
Prospective validation of the EASL-EASD algorithm for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes
inferred← citeshttps://doi.org/10.17235/reed.2026.12025/2026openalex-snapshot
Screening for Advanced Liver Disease in Type 2 Diabetes: Time for Systematic Implementation
inferred← citeshttps://doi.org/10.21037/hbsn-23-563openalex-snapshot
Advancing towards accurate phenotyping based on metabolic and fibrosis risk in metabolic-dysfunction associated steatotic liver disease: one step closer to personalized care
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3960262/v1openalex-snapshot
A parallel randomised trial testing community fibrosis assessment for suspected non-alcoholic fatty liver disease: Outcomes from LOCATE-NAFLD
inferred← citeshttps://doi.org/10.2139/ssrn.4885143openalex-snapshot
Screening for Advanced Liver Fibrosis Due to MASLD with VCTE Alongside Retina Scanning in Patients with Type 2 Diabetes: A Cross-Sectional Study of 1,005 Patients
inferred← citeshttps://doi.org/10.2147/ppa.s468705openalex-snapshot
An Australian Community-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Care Pathway for People with Type 2 Diabetes: Barriers and Considerations
inferred← citeshttps://doi.org/10.21518/ms2024-532openalex-snapshot
Thioredoxin-interacting protein TXNIP as a promising diagnostic marker for metabolic-associated fatty liver disease in patients with type 2 diabetes
inferred← citeshttps://doi.org/10.2337/dc24-1236openalex-snapshot
Steatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes
inferred← citeshttps://doi.org/10.2337/dc24-2075openalex-snapshot
Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study
inferred← citeshttps://doi.org/10.2337/dc25-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
inferred← citeshttps://doi.org/10.2337/dc26-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026
inferred← citeshttps://doi.org/10.2337/dci23-0027openalex-snapshot
Hunting for Progressive NAFLD in Type 2 Diabetes: Do Not Trust Liver Enzymes!
inferred← citeshttps://doi.org/10.2337/dci24-0094openalex-snapshot
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
inferred← citeshttps://doi.org/10.2337/dsi23-0013openalex-snapshot
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
inferred← citeshttps://doi.org/10.2337/dsi23-0014openalex-snapshot
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know
inferred← citeshttps://doi.org/10.2337/dsi23-0015openalex-snapshot
Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action
inferred← citeshttps://doi.org/10.31146/1682-8658-ecg-240-8-5-12openalex-snapshot
Risk factors of advanced fibrosis in non-alcoholic fatty liver disease, associated with type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.3350/cmh.2024.0246openalex-snapshot
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.3350/cmh.2024.0330openalex-snapshot
Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fendo.2024.1420088openalex-snapshot
Serum 25-hydroxy vitamin D level is associated with elastography-detected liver fibrosis in patients with type 2 diabetes mellitus in China
inferred← citeshttps://doi.org/10.3389/fped.2025.1675713openalex-snapshot
The evolving landscape of pediatric obesity and metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.3389/fphar.2026.1789019openalex-snapshot
Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives
inferred← citeshttps://doi.org/10.3390/biomedicines12081739openalex-snapshot
Assessment of the Liver Steatosis and Fibrosis Risk in Metabolic Syndrome and Its Individual Components, Considering the Varying Definitions Used in Clinical Practice throughout Time: A Retrospective Cross-Sectional Study
inferred← citeshttps://doi.org/10.3390/biomedicines13020359openalex-snapshot
Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.3390/biomedicines13123045openalex-snapshot
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort
inferred← citeshttps://doi.org/10.3390/diagnostics15131591openalex-snapshot
Tips for Hepatologist Referral of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease with Alanine Aminotransferase Levels ≤ 30 U/L
inferred← citeshttps://doi.org/10.3390/ijms25147621openalex-snapshot
Metabolic Crosstalk between Liver and Brain: From Diseases to Mechanisms
inferred← citeshttps://doi.org/10.3390/jcm12175597openalex-snapshot
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
inferred← citeshttps://doi.org/10.3390/jcm14093155openalex-snapshot
Modifiable and Non-Modifiable Risk Factors and Vascular Damage Progression in Type 2 Diabetes: A Primary Care Analysis
inferred← citeshttps://doi.org/10.3390/jcm15010050openalex-snapshot
Use of FibroScan-AST (FAST) Score and Fibrosis-4 Index to Identify Advanced Liver Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.3390/jcm15166421openalex-snapshot
Determinants of Metabolic Dysfunction-Associated Steatotic Liver Diseases in Patients with Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.3390/medicina60060862openalex-snapshot
Decreased Hepatic and Serum Levels of IL-10 Concur with Increased Lobular Inflammation in Morbidly Obese Patients
inferred← citeshttps://doi.org/10.3390/nu18061014openalex-snapshot
Physiological Regulation of Nutritional and Metabolic Biomarkers in Obesity: Implications for Precision Nutrition
inferred← citeshttps://doi.org/10.3748/wjg.v30.i22.2839openalex-snapshot
Screening for metabolic dysfunction-associated fatty liver disease: Time to discard the emperor’s clothes of normal liver enzymes?
inferred← citeshttps://doi.org/10.4081/ltj.2025.403openalex-snapshot
Effects of laser acupuncture (stress-free therapy) on blood liver function indicators
inferred← citeshttps://doi.org/10.4103/ijdt.ijdt_22_25openalex-snapshot
Adiposity-based Chronic Diseases and the Therapeutic Role of Glucagon-like Peptide-1 Receptor Agonists
inferred← citeshttps://doi.org/10.4254/wjh.v17.i7.107675openalex-snapshot
Link between type 2 diabetes mellitus and hepatocellular carcinoma
inferred← citeshttps://doi.org/10.4254/wjh.v18.i1.111534openalex-snapshot
Noninvasive liver fibrosis assessment in metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.4254/wjh.v18.i3.113284openalex-snapshot
Metabolically associated fatty liver disease: What hepatologists need to know about this systemic disease
inferred← citeshttps://doi.org/10.5662/wjm.v14.i2.91319openalex-snapshot
Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies
inferred← citeshttps://doi.org/10.5937/jomb0-53123openalex-snapshot
Changes in serum cholyglycine and prealbumin levels, glutamyl transpeptidase, and Alpha-fetoprotein after transcatheter arterial chemoembolisation combined with microwave ablation of liver cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.26674463openalex-snapshot
Additional file 1 of Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.